Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4059
-0.0025-0.61%
At close: Jun 11, 5:00 PM EST
$0.4100
0.00411.01%
After Hours: 6:28 PM EST
Heron Therapeutics Inc Analyst Ratings
HRTXNASDAQ
Heron Therapeutics Analyst Ratings and Price Targets | NASDAQ:HRTX | Benzinga
Heron Therapeutics Inc has a consensus price target of $5 based on the ratings of 4 analysts. The high is $7 issued by Rodman & Renshaw on June 13, 2024. The low is $2 issued by HC Wainwright & Co. on June 3, 2026. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Needham on June 3, 2026, January 9, 2026, and August 8, 2025, respectively. With an average price target of $3.67 between HC Wainwright & Co., HC Wainwright & Co., and Needham, there's an implied 794.31% upside for Heron Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Rodman & Renshaw
Capital One
1calculated from analyst ratings
Analyst Ratings for Heron Therapeutics
Loading calendar...
FAQ
What is the target price for Heron Therapeutics (HRTX) stock?
The latest price target for Heron Therapeutics (NASDAQ:HRTX) was reported by HC Wainwright & Co. on June 3, 2026. The analyst firm set a price target for $2.00 expecting HRTX to rise to within 12 months (a possible 387.80% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
The latest analyst rating for Heron Therapeutics (NASDAQ:HRTX) was provided by HC Wainwright & Co., and Heron Therapeutics maintained their buy rating.
When was the last upgrade for Heron Therapeutics (HRTX)?
There is no last upgrade for Heron Therapeutics
When was the last downgrade for Heron Therapeutics (HRTX)?
The last downgrade for Heron Therapeutics Inc happened on June 3, 2026 when Needham changed their price target from N/A to N/A for Heron Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on June 3, 2026 so you should expect the next rating to be made available sometime around June 3, 2027.
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a maintained with a price target of $4.00 to $2.00. The current price Heron Therapeutics (HRTX) is trading at is $0.41, which is out of the analyst’s predicted range.
